Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 80

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Primary immunodeficiency syndrome

Not recruiting

Long-term safety and effectiveness study of leniolisib for patients with primary immunodeficiency and immune system problems

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Leniolisib Phosphate
  • Sponsor:Pharming Technologies B.V.

Vitiligo

Not recruiting

A Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Conjunctivitis allergic+1

Not recruiting

Testing sublingual immunotherapy with dermatophagoides pteronyssinus extract for adults with moderate to severe house dust mite allergy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dermatophagoides Pteronyssinus Extract
  • Sponsor:ROXALL Medizin GmbH

Psoriasis

Not recruiting

Testing IDOR-1117-2520 for Adults with Moderate to Severe Chronic Plaque Psoriasis With or Without Psoriatic Arthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:IDOR-1117-2520C
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Systemic scleroderma+3

Not recruiting

A Study of Cizutamig for Patients with Severe Autoimmune Inflammatory Diseases That Did Not Respond to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Immune thrombocytopenia

Not recruiting

A Study to Test How Safe Budoprutug Is and How Well It Works in Patients with Immune Thrombocytopenia

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BUDOPRUTUG
  • Sponsor:Climb Bio Inc.

Autoimmune disorder

Not recruiting

Study Using PET Imaging to See How [89Zr]Zr-DFO-CIT-013 Spreads in Patients with Inflammatory Mediated Immune Diseases

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:[89ZR]ZR-DFO-CIT-013
  • Sponsor:Citryll B.V.

Rheumatoid arthritis

Not recruiting

A study testing tulisokibart for people with rheumatoid arthritis who have not responded well enough to previous treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Transplant rejection

Not recruiting

A study testing ALXN2030 for adults with antibody-mediated rejection after kidney transplantation

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:RNA, (AM-SP-UM-CM-AM-AM-CM-UM-(2'-DEOXY-2'-FLUORO)C-(2'-DEOXY-2'-FLUORO)A-(2'-DEOXY-2'-FLUORO)C-(2'-DEOXY-2'-FLUORO)C-UM-GM-UM-AM-AM-UM-AM-AM-AM-GM-CM-AM-GM-CM-CM-GM-[2'-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-[2'-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-[2'-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-GM-GM-CM-UM-GM-CM), COMPLEX WITH RNA ([4'-DE(HYDROXYMETHYL)-4'-[(HYDROXYMETHOXYPHOSPHINYL)METHOXY]]UM-SP-(2'-DEOXY-2'-FLUORO)U-SP-(2'-DEOXY-2'-FLUORO)U-(2'-DEOXY-2'-FLUORO)A-(2'-DEOXY-2'-FLUORO)U-UM-(2'-DEOXY-2'-FLUORO)A-CM-AM-(2'-DEOXY-2'-FLUORO)G-GM-UM-GM-(2'-DEOXY-2'-FLUORO)A-GM-UM-UM-GM-AM-UM-SP-GM-SP-GM)
  • Sponsor:Alexion Pharmaceuticals Inc.

Immune thrombocytopenia

Not recruiting

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Food allergy

Not recruiting

Study of DBV712 skin patch safety in children aged 1-3 years with peanut allergy

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Water For Injection
  • Sponsor:Dbv Technologies

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.